

Amendments to the Claims:

1. (Original) A polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9 °C, and an exotherm at between 279.3 and 281.3 °C.
2. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 1, the polymorph being further characterizable as having, by differential scanning calorimetry, an endotherm at between 274.4 to 275.3 °C, and an exotherm at between 279.8 and 280.8 °C.
3. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 1, the polymorph being further characterizable as having, by differential scanning calorimetry, an endotherm at between 274.7 to 275.1 °C, and an exotherm at between 280.1 and 280.5 °C.
4. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 1, the polymorph being further characterizable as having, by differential scanning calorimetry, an endotherm at between 274.8 to 275.0 °C, and an exotherm at between 280.2 and 280.4 °C.
5. (Original) A polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9 °C, and an exotherm at between 279.3 and 281.3 °C.
6. (Original) A polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, for Cu $K\alpha$ radiation of wavelength of 1.5406 Angstrom, an X-ray powder diffraction pattern with diffraction lines at 2θ values 4.8, 14.2, 19.1 and 26.8.
7. (Currently Amended) A polymorphic form of 9-nitrocamptothecin ~~in a form~~ crystallized from acetonitrile.

8. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 7, the polymorph being characterizable as having, differential scanning calorimetry, an endotherm at between 273.9 to 275.9 °C, and an exotherm at between 279.3 and 281.3 °C.
9. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 7, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at $^{\circ}2\theta$ values 4.8, 14.2, 19.1 and 26.8 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.
10. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 7, the polymorph being characterizable as having, for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom, an X-ray powder diffraction pattern with diffraction lines at $^{\circ}2\theta$ values 4.8, 14.2, 19.1 and 26.8.
11. (Original) A pharmaceutical composition comprising:
a pharmaceutical carrier; and
a polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9 °C, and an exotherm at between 279.3 and 281.3 °C.
12. (Original) A pharmaceutical formulation according to claim 11, the polymorph being further characterizable as having, by differential scanning calorimetry, an endotherm at between 274.4 to 275.3 °C, and an exotherm at between 279.8 and 280.8 °C.
13. (Original) A pharmaceutical formulation according to claim 11, the polymorph being further characterizable as having, by differential scanning calorimetry, an endotherm at between 274.7 to 275.1 °C, and an exotherm at between 280.1 and 280.5 °C.
14. (Original) A pharmaceutical formulation according to claim 11, the polymorph being further characterizable as having, by differential scanning calorimetry, an endotherm at between 274.8 to 275.0 °C, and an exotherm at between 280.2 and 280.4 °C.

15. (Original) A pharmaceutical composition comprising:
a pharmaceutical carrier; and
a polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9 °C, and an exotherm at between 279.3 and 281.3 °C.
16. (Original) A pharmaceutical composition comprising:
a pharmaceutical carrier; and
a polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, for Cu $K\alpha$ radiation of wavelength of 1.5406 Angstrom, an X-ray powder diffraction pattern with diffraction lines at 2θ values 4.8, 14.2, 19.1 and 26.8.
17. (Original) A pharmaceutical composition comprising:
a pharmaceutical carrier; and
a polymorphic form of 9-nitrocamptothecin crystallized from acetonitrile.
18. (Original) A pharmaceutical formulation according to claim 17, the polymorph being characterizable as having, differential scanning calorimetry, an endotherm at between 273.9 to 275.9 °C, and an exotherm at between 279.3 and 281.3 °C.
19. (Original) A pharmaceutical formulation according to claim 17, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2θ values 4.8, 14.2, 19.1 and 26.8 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.
20. (Original) A method of preparing a polymorphic form of 9-nitrocamptothecin, the method comprising:
crystallizing 9-nitrocamptothecin from acetonitrile.
21. (Original) A method according to claim 20, the polymorph being characterizable as having, differential scanning calorimetry, an endotherm at between 273.9 to 275.9 °C, and an exotherm at between 279.3 and 281.3 °C.

22. (Original) A method according to claim 20, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2θ values 4.8, 14.2, 19.1 and 26.8 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.